Halliburton has named its latest cohort. Photo via Getty Images

Seven companies from around the world have been invited to join Halliburton Labs, the company announced today.

Halliburton Labs is an incubator program that helps early-stage energy tech companies through connections, access to facilities, and more.

"We are pleased to welcome these promising energy startups and provide customized support to help them achieve their specific priorities, accelerate commercialization, and increase valuation," says Dale Winger, managing director of the program, in a news release. "Our experienced practitioners and network will help these companies use their time and capital efficiently."

The next Halliburton Labs Finalists Pitch Day, which will feature the ongoing cohort, is planned for Thursday, March 14, in New Orleans in coordination with New Orleans Entrepreneur Week and 3rd Coast Venture Summit. Applications for the program are open until Friday, February 9.

The newest additions to Halliburton Labs are as follows.

One of three Israel-based companies in the cohort, Airovation Technologies is advancing carbon capture and utilization solutions through helping hard-to-abate industries that achieve emissions reduction targets through its proprietary carbon mineralization technology. Through transforming point-source CO2 emissions into circular chemicals and building materials, Airovation is developing a scalable pathway for industrial emitters to decarbonize with multiple revenue streams.

“Industrial emitters are seeking economic ways to decarbonize,” Marat Maayan, founder and CEO at Airovation Technologies, says. “We are excited to accelerate our commercialization in the United States with Halliburton Labs, leveraging their expertise, capabilities and network."

Ayrton Energy, based in Calgary, is developing liquid organic hydrogen carrier storage technology to enable the large-scale, efficient transportation of hydrogen over extended distances without hydrogen loss and pipeline corrosion. This storage technology provides a high-density hydrogen storage medium without the need for cryogenics or high-pressure systems, which differs from the existing technology out there. This improves the safety and efficiency of hydrogen storage while enabling the use of existing fuel infrastructure for transportation, including tanks, transport trucks, and pipelines.

“Our mission is to enable hydrogen adoption by solving the key challenges in hydrogen storage and transportation,” Ayrton CEO Natasha Kostenuk says.

Cache Energy, based out of the University of Illinois Research Park, is developing a new long duration energy storage solution, which scales to interseasonal durations, through a low-cost solid fuel. Once charged, the storage material stores energy at room temperature, with near zero loss in time and can be safely stored and transported anywhere energy is needed.

“We are strong believers of leveraging existing infrastructure and expertise to fast track decarbonization goals,” Arpit Dwivedi, founder and, says CEO of Cache Energy. “We look forward to this collaboration and learning from Halliburton's manufacturing and operational expertise, as we scale our technology.”

From Be'er Sheva City in Israel, CENS develops enhanced dry dispersion technology based on dry-treated carbon nanotubes that enable high energy density, high power, and outstanding cycle performance in Li-ion batteries. The technology is differentiated because it can be applied to any type of lithim-ion battery and its implementation can be seamlessly integrated into the production line.

“Our goal is to develop ground-breaking technologies that will become disruptive technologies to market at a massive scale,” says CEO Moshe Johary. “With the help and vast experience of Halliburton Labs' team, we could achieve advancements in production capabilities while extending our footprint in the market.”

Casper, Wyoming-based Disa Technologies provides solutions to the mining and remediation industries. Disa utilizes patented minerals liberation technology to more efficiently isolate target minerals and mitigate environmental impacts to its users. Disa platforms treat a wide array of critical minerals that are essential to the economy and our way of life.

“We are excited to have Halliburton's support as we scale-up our technology and deliver innovative minerals processing solutions that disrupt industry best practices, enhance global resource utilization, and benefit the environment and the communities we serve," Greyson Buckingham, Disa's CEO and president, says.

Marel Power Solutions, headquartered from Michigan, is innovating electrification through its novel powerstack technology. These materials-efficient, quickly deployable, and scalable power-stacks, encapsulating advanced cooling technology, redefine power conversion in mobility, industrial, and renewables spaces.

“We're thrilled to contribute to global climate sustainability. Our collaboration with Halliburton will accelerate the electrification transition across industries. Marel's technology not only maximizes heat evacuation from densely packed power semiconductors but, more importantly, offers substantial savings in cost, weight, size, and time, making it transformative in the evolving landscape of electrification,” Marel CEO Amrit Vivekanand says.

And lastly, XtraLit is an Israeli company that develops a technology for direct lithium extraction from brines. The technology enables efficient and economically justified processing of brines even with relatively low lithium concentrations. Application of the extraction technology will allow mineral providers to unlock new significant sources of lithium that are critical to meet growing demand.

“Oil and gas industry produced waters might become a substantial resource for lithium production,” says XtraLit CEO, Simon Litsyn. “XtraLit will cooperate with Halliburton on optimization of produced water treatment for further increasing the efficiency of the lithium extraction process.”

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.